# Indaptus Therapeutics, Inc.: overview INDP · Nasdaq · CIK 1857044 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/indp.md) · [Financials](/companies/indp/financials.md) · [Filings](/companies/indp/filings.md) · [Insiders](/companies/indp/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(9.04)](/filings/0001493152-25-021759.md) | not reported | [(9.11)](/filings/0001493152-26-023362.md) | [(9.09)](/filings/0001493152-26-037579.md) | [(2.98)](/filings/0001493152-25-021759.md) | not reported | [(0.23)](/filings/0001493152-26-023362.md) | [(0.02)](/filings/0001493152-26-037579.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.89)](/filings/0001493152-22-007319.md) | [(1.73)](/filings/0001493152-24-009769.md) | [(1.83)](/filings/0001493152-25-010136.md) | [(44.96)](/filings/0001493152-26-010585.md) | [(21.58)](/filings/0001493152-26-010585.md) | | Free cash flow | $m | [(11.3)](/filings/0001493152-23-008010.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/indp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $169.4k | 56,470 | | Added +29,463 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $161.4k | 53,811 | | New +53,811 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $101.0k | 33,652 | | New +33,652 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $41.9k | 13,967 | | New +13,967 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $34.8k | 11,586 | | New +11,586 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $26.8k | 8,936 | | Added +6,239 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.4k | 478 | | New +478 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $618 | 206,077 | | New +206,077 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $51 | 17 | | Unchanged | | [CWM, LLC](/funds/1535847.md) | 2026-03-31 | $4 | 2 | | Not compared | ## Recent filings [All 343 filings](/companies/indp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:06 ET | [SCHEDULE 13D/A](/filings/0001829126-26-011445.md) | Ownership report, active investor, amended | 0001829126-26-011445 | | 2026-10-22 | 20:05 ET | [SCHEDULE 13D/A](/filings/0001829126-26-011444.md) | Ownership report, active investor, amended | 0001829126-26-011444 | | 2026-10-22 | 20:05 ET | [SCHEDULE 13D/A](/filings/0001829126-26-011443.md) | Ownership report, active investor, amended | 0001829126-26-011443 | | 2026-10-21 | 20:05 ET | [SCHEDULE 13D/A](/filings/0001829126-26-011386.md) | Ownership report, active investor, amended | 0001829126-26-011386 | | 2026-10-20 | 20:38 ET | [8-K](/filings/0001493152-26-047770.md) | 8.01 Other events | 0001493152-26-047770 | | 2026-09-30 | 13:05 ET | [8-K](/filings/0001493152-26-045040.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-045040 | | 2026-09-10 | 01:45 ET | [8-K](/filings/0001493152-26-042037.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-042037 | | 2026-09-08 | 01:55 ET | [8-K/A](/filings/0001493152-26-041636.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-041636 | | 2026-09-04 | 20:05 ET | [8-K](/filings/0001493152-26-041532.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-041532 | | 2026-09-01 | 11:30 ET | [8-K](/filings/0001493152-26-040926.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-040926 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010585.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1857044 - Tickers: INDP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.